- Home
- AMPY vs ALXO Comparison
AMPY vs ALXO Comparison
Compare AMPY & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMPY | ALXO |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.8M | 205.9M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMPY | ALXO |
|---|---|---|
| Price | $4.38 | $1.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $7.75 | $4.60 |
| AVG Volume (30 Days) | 478.5K | ★ 930.4K |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.26 | 26.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,637,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.65 | $1.05 |
| 52 Week High | $6.79 | $2.66 |
Technical Indicators
Market Signals| Indicator | AMPY | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 29.67 |
| Support Level | $3.86 | $1.37 |
| Resistance Level | $5.07 | $1.56 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 12.31 | 12.32 |
Price Performance
Historical ComparisonAbout AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The companies oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.